BNTX250117P190000
- 88.70
- 0.000.00%
BioNTech Newsroom
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Vertex Pharmaceuticals (VRTX) and Ascendis Pharma (ASND)
Jefferies Maintains BioNTech(BNTX.US) With Buy Rating, Raises Target Price to $154.43
BioNTech SE's Strategic and Clinical Advancements Drive Buy Rating on BNT327's Promise in Oncology
J.P. Morgan Maintains BioNTech(BNTX.US) With Hold Rating, Announces Target Price $122
J.P. Morgan Reaffirms Their Hold Rating on BioNTech SE (BNTX)
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
Morgan Stanley Sticks to Its Buy Rating for BioNTech SE (BNTX)
FDA Lifts Hold on BioNTech's Key Cancer Trial
Express News | Evonik Industries - Both Segments Currently Have Annual Sales of Around EUR 6 Bln Each
Express News | Evonik Industries - to Reduce Number of Management Levels From Average of Ten to Maximum of Six by End of 2026
Express News | Evonik Industries - to Organize Its Business Lines in Two New Segments: Custom Solutions and Advanced Technologies
Express News | Evonik Industries CEO: 2024 Is a Good Year for Evonik
Ryvu Therapeutics Provides an Update on RVU120 Phase II Program
Jefferies Maintains BioNTech(BNTX.US) With Buy Rating, Cuts Target Price to $149
BioNTech Analyst Ratings
Wells Fargo Initiates BioNTech(BNTX.US) With Buy Rating, Announces Target Price $170
J.P. Morgan Maintains BioNTech(BNTX.US) With Hold Rating
BioNTech SE: Promising Developments in Triple-Negative Breast Cancer Amid Cautious Optimism
BioNTech SE's Promising Future: Buy Rating Backed by Breakthrough Cancer Therapy and Expansive Pipeline
Strategic Combinations Propel BioNTech's B7-H3 ADC BNT324 Amidst Competitive Landscape: Analyst 'Buy' Rating